Technical Analysis for NEXI - NexImmune, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 10.67 | -10.93% | -1.31 |
NEXI closed down 10.93 percent on Friday, July 23, 2021, on approximately normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Historical NEXI trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Expansion Breakdown | Bearish Swing Setup | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -10.93% | |
| Wide Bands | Range Expansion | -10.93% | |
| Oversold Stochastic | Weakness | -10.93% | |
| Wide Bands | Range Expansion | -16.18% | |
| Oversold Stochastic | Weakness | -16.18% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock. | |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation (AIM) technology. The company has two product candidates in human trials, including NEXI-001 in acute myeloid leukemia, or AML; and NEXI-002 in multiple myeloma, or MM. NexImmune, Inc. was founded in 2011 and is headquartered in Gaithersburg, Maryland.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Immunotherapy Acute Myeloid Leukemia Immunotherapies Leukemia Multiple Myeloma Immune Mediated Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 28.0 |
| 52 Week Low | 10.65 |
| Average Volume | 28,553 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 16.24 |
| 20-Day Moving Average | 13.87 |
| 10-Day Moving Average | 12.50 |
| Average True Range | 1.05 |
| ADX | 41.96 |
| +DI | 9.44 |
| -DI | 32.05 |
| Chandelier Exit (Long, 3 ATRs) | 13.59 |
| Chandelier Exit (Short, 3 ATRs) | 13.81 |
| Upper Bollinger Bands | 17.12 |
| Lower Bollinger Band | 10.62 |
| Percent B (%b) | 0.01 |
| BandWidth | 46.83 |
| MACD Line | -1.37 |
| MACD Signal Line | -1.22 |
| MACD Histogram | -0.1467 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 13.47 | ||||
| Resistance 3 (R3) | 13.77 | 13.14 | 13.00 | ||
| Resistance 2 (R2) | 13.14 | 12.43 | 12.99 | 12.85 | |
| Resistance 1 (R1) | 11.91 | 11.99 | 11.59 | 11.60 | 12.69 |
| Pivot Point | 11.28 | 11.28 | 11.12 | 11.13 | 11.28 |
| Support 1 (S1) | 10.04 | 10.57 | 9.73 | 9.74 | 8.65 |
| Support 2 (S2) | 9.41 | 10.13 | 9.26 | 8.49 | |
| Support 3 (S3) | 8.18 | 9.41 | 8.34 | ||
| Support 4 (S4) | 7.87 |
